Causaly
Created in 2018
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
1,415 21,638Activities
Technologies
Entity types
Location
10-16 Elm St, London WC1X 0BJ, UK
London
United Kingdom
Employees
Scale: 51-200
Estimated: 126
Engaged corporates
6
0 4Added in Motherbase
2 years, 11 months ago
biotech Value proposition
Unlock R&D productivity with the most complete AI platform for life sciences.
Our mission at Causaly is to redefine the boundaries of human discovery by harnessing transformative AI technologies. Founded in 2018, Causaly’s unique AI platform is a powerful catalyst for the modern Life Science research organization, reshaping how data is found, analyzed and applied in critical decision-making processes in drug discovery and development.
Supporting a broad range of complex knowledge workflows, our platform accelerates the journey from bench research and laboratory insights to the launch of life-changing therapies.
Artificial Intelligence, Natural Language Understanding, Knowledge graphs, Pharma, and Life Sciences
Causaly: The Most Complete AI Platform For Life Sciences
Causaly is the only platform that combines advanced AI and a high-precision knowledge graph to reduce risk and increase R&D productivity at scale.
https://www.causaly.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 14 Jul 2023 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 7 Jul 2023 | | |
 Sifted Newspaper Publishing | Sifted Newspaper Publishing | Other 9 Apr 2024 | | |
 Illumina For Startups Startup accelerator & VC, Biotechnology, Biotechnology Research | Illumina For Startups Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 20 Apr 2021 | | |
 Entrepreneur First Startup accelerator & VC, Venture Capital and Private Equity Principals | Entrepreneur First Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 24 Mar 2020 | | |
 Novartis Pharmaceutical, Pharmaceutical Manufacturing | Novartis Pharmaceutical, Pharmaceutical Manufacturing | Other 29 Oct 2024 | | |